IRADIMED Framtida tillväxt
Future kriterier kontrolleras 1/6
IRADIMED förväntas öka vinsten och intäkterna med 10.9% och 9.6% per år respektive medan EPS förväntas växa med 10.7% per år.
Viktig information
10.9%
Tillväxttakt i vinsten
10.70%
Tillväxttakt för EPS
| Medical Equipment vinsttillväxt | 16.4% |
| Intäkternas tillväxttakt | 9.6% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 07 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Analysartikel • Jun 22
IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative
With no single headline event driving attention to IRADIMED (IRMD) today, investors are instead looking at the stock’s recent performance record and financial profile to reassess how it fits into a healthcare portfolio. See our latest analysis for IRADIMED. IRADIMED’s share price has been choppy in recent months, with the stock down around 7% over 90 days and 3% year to date, yet its 1 year total shareholder return of about 61% and 5 year total shareholder return above 250% still point to...
Uppdatering av berättelse • Jun 18
IRMD: 2026 Guidance And Bullish Initiation Will Drive Further Re Rating
Analysts have maintained their $118 price target on IRADIMED, citing recent bullish initiation and supporting research that highlight the company's long-term earnings potential, along with a still-elevated forward P/E profile. What’s in the News for IRADIMED IRADIMED issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.0 million to US$21.0 million and GAAP diluted EPS between US$0.40 and US$0.44.Uppdatering av berättelse • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Uppdatering av berättelse • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Uppdatering av berättelse • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Uppdatering av berättelse • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Uppdatering av berättelse • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Uppdatering av berättelse • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Uppdatering av berättelse • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Uppdatering av berättelse • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Uppdatering av berättelse • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Uppdatering av berättelse • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Uppdatering av berättelse • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Uppdatering av berättelse • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Uppdatering av berättelse • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Analysartikel • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Analysartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Analysartikel • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Ny berättelse • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Analysartikel • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Analysartikel • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Analysartikel • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Analysartikel • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Analysartikel • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 113 | 32 | 18 | 30 | 1 |
| 12/31/2027 | 101 | 28 | 22 | 28 | 2 |
| 12/31/2026 | 91 | 25 | 18 | 23 | 2 |
| 3/31/2026 | 86 | 24 | 24 | 29 | N/A |
| 12/31/2025 | 84 | 22 | 17 | 25 | N/A |
| 9/30/2025 | 81 | 21 | 14 | 25 | N/A |
| 6/30/2025 | 78 | 21 | 13 | 27 | N/A |
| 3/31/2025 | 75 | 20 | 14 | 26 | N/A |
| 12/31/2024 | 73 | 19 | 17 | 26 | N/A |
| 9/30/2024 | 71 | 19 | 17 | 24 | N/A |
| 6/30/2024 | 69 | 19 | 13 | 16 | N/A |
| 3/31/2024 | 68 | 18 | 11 | 13 | N/A |
| 12/31/2023 | 66 | 17 | 5 | 13 | N/A |
| 9/30/2023 | 63 | 16 | 5 | 13 | N/A |
| 6/30/2023 | 60 | 15 | 7 | 15 | N/A |
| 3/31/2023 | 56 | 14 | 5 | 13 | N/A |
| 12/31/2022 | 53 | 13 | 8 | 10 | N/A |
| 9/30/2022 | 50 | 13 | 9 | 10 | N/A |
| 6/30/2022 | 48 | 12 | 9 | 10 | N/A |
| 3/31/2022 | 45 | 10 | 11 | 12 | N/A |
| 12/31/2021 | 42 | 9 | 11 | 11 | N/A |
| 9/30/2021 | 38 | 6 | 10 | 10 | N/A |
| 6/30/2021 | 35 | 5 | 8 | 8 | N/A |
| 3/31/2021 | 32 | 1 | 5 | 6 | N/A |
| 12/31/2020 | 32 | 1 | 5 | 6 | N/A |
| 9/30/2020 | 34 | 4 | 7 | 7 | N/A |
| 6/30/2020 | 36 | 5 | 8 | 9 | N/A |
| 3/31/2020 | 39 | 10 | 10 | 11 | N/A |
| 12/31/2019 | 39 | 10 | N/A | 10 | N/A |
| 9/30/2019 | 36 | 8 | N/A | 10 | N/A |
| 6/30/2019 | 34 | 8 | N/A | 7 | N/A |
| 3/31/2019 | 32 | 7 | N/A | 6 | N/A |
| 12/31/2018 | 30 | 6 | N/A | 7 | N/A |
| 9/30/2018 | 29 | 5 | N/A | 5 | N/A |
| 6/30/2018 | 27 | 3 | N/A | 6 | N/A |
| 3/31/2018 | 25 | 2 | N/A | 5 | N/A |
| 12/31/2017 | 23 | 0 | N/A | 3 | N/A |
| 9/30/2017 | 22 | 1 | N/A | 4 | N/A |
| 6/30/2017 | 24 | 3 | N/A | 6 | N/A |
| 3/31/2017 | 29 | 5 | N/A | 7 | N/A |
| 12/31/2016 | 32 | 7 | N/A | 9 | N/A |
| 9/30/2016 | 35 | 8 | N/A | 10 | N/A |
| 6/30/2016 | 35 | 9 | N/A | 9 | N/A |
| 3/31/2016 | 33 | 8 | N/A | 9 | N/A |
| 12/31/2015 | 31 | 8 | N/A | 8 | N/A |
| 9/30/2015 | 26 | 5 | N/A | 4 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: IRMD s prognostiserade vinsttillväxt ( 10.9% per år) är över sparkvoten ( 3.5% ).
Resultat vs marknad: IRMD s intäkter ( 10.9% per år) förväntas växa långsammare än marknaden för US ( 18.2% per år).
Höga tillväxtresultat: IRMD s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: IRMD s intäkter ( 9.6% per år) förväntas växa långsammare än marknaden för US ( 13% per år).
Hög tillväxtintäkter: IRMD s intäkter ( 9.6% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om IRMD s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/12 05:45 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
IRADIMED CORPORATION bevakas av 4 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |